Date : Feb 2021

Report-ID : 171

Category : Healthcare, Pharmaceutics and Medical Devices


Choose License

The global Graft Versus Host Disease market expected to grow; at a CAGR of XX % during the forecast period 2019- 2026. Graft versus host disease (GVHD) is an immune-mediated disease resulting from a complex interaction between donor and recipient adaptive immunity. Source: Secondary Databases, Primary Interviews and 99-Reports AnalysisMarket Overview Graft versus host disease affects different parts of the patientís body. It most commonly affects the digestive system, liver, and skin. It is tough to predict who might develop graft versus host disease after a bone marrow or stem cell transplant. Chances of a graft versus host disease are reduced or symptoms are milder if the donorís cells match closely with that of the recipient's. The global graft versus host disease market is expected to grow at a CAGR of 14% from 2018-2026. Market Dynamics Graft versus host disease can be identified on the basis of severity i.e. acute, chronic and prophylactic. The symptoms mainly include skin problems, diarrhea, nausea, abdominal pain and liver failure.As per the Center for International Blood and Marrow Transplant Research, there are around 25,000 allogeneic immature microorganism transplants are performed every year all inclusive, influences half or a greater amount of beneficiaries, practically beyond what half of these cases could have been kept away from with the accessibility of legitimate restorative gear and gadgets for human services techniques. This critical number is required to go about as a driver to the market development. In addition high investment in the research and development is expected to drive the growth of the market. Furthermore advancements in the diagnostic measures of the disease are driven the market Global Graft Versus Host Disease.
Global Graft Versus Host Disease Market - Key Segment
Global Graft Versus Host Disease market is segmented into -
By Disease
graft versus host disease (aGvHD)
chronic graft versus host disease (cGvHD)
By Treatment
mTOR inhibitors
tyrosine kinase inhibitors
monoclonal antibodies
Etanercept
Thalidomide.
By Distribution Channel
Hospital
Retail
Online
Global Graft Versus Host Disease Market - Geographical Analysis By geography, the global Graft Versus Host Disease Market is segmented into North America, Asia-Pacific (APAC), Europe, South America, and the Middle East and Africa (MEA).In North America and Asia Pacific is assessed to extend at a quick rate because of an enormous occurrence and commonness pace of the worldwide join versus have sickness. For example, an exploration study proposes that around 30% to half of hematopoietic undifferentiated cell transplant (HSCT) beneficiaries create intense GVHD. That means 5500 patients/year who will create intense GVHD. In the long run, around half of patients with intense unite versus have ailment have appearances of incessant join versus have illness. The worldwide join versus have sickness treatment showcase in Europe is additionally assessed to extend because of an ascent in the geriatric populace with malignant growth ailment, upgrades in therapeutic research, and increment in clinical preliminaries. The join versus have illness treatment showcase in different topographies is explicitly determined by the selection of cutting edge innovations in malignant growth treatment, increment in mindfulness about sicknesses, and ascend in the quantity of chemotherapy medicines. Global Graft Versus Host Disease Market -
Competitive Analysis
Sanofi
Novartis AG
Neovii Biotech
Merck & Co Inc
Astellas Pharma Inc.
Soligenix Inc
Mesoblast Ltd.
Johnson & Johnson Services Inc.Mallinckrodft
ElsaLys Biotech SA
Incyte Corporation
Kiadis Pharma
TABLE OF CONTENT
1. Introduction
1.1. Market Definition
1.2. Purpose of the Report
1.3. Currency
1.4. Limitations
1.5. Stakeholders

2. Research Methodology
2.1. Research Scope
2.2. Market Segmentation
2.3. Research Approach
2.3.1. Top-Down Approach
2.3.2. Bottom-Up Approach
2.4. Primary Research
2.5. Secondary Research
2.6. Assumptions
3. Executive Summary
3.1. Global Market Snapshot, by Geography
3.2. Graft Versus Host Disease Market, By Spectrum Range
3.3. Graft Versus Host Disease Market, By Functionally Range
3.4. Graft Versus Host Disease Market, By End User

3.5. Graft Versus Host Disease Market, by Industry Vertical
3.6. Competitive Landscape

4. Market Overview
4.1. Market Dynamics
4.1.1. Driving Forces
4.1.1.1. Commercial adoption of digitalization
4.1.1.2. High adoption of cloud services by banking sector
4.1.1.3. Growing advancement in digital technology
4.1.1.4. Driver 4
4.1.2. Restraining Factors
4.1.2.1. Increasing risk of Cyber threats
4.1.2.2. Privacy Concerns
4.1.2.3. Restraint 3
4.1.3. Opportunity Matrix
4.1.3.1. Opportunity 1
4.1.3.2. Opportunity 2
4.1.4. Challenges
4.1.4.1. Challenge 1
4.1.4.2. Challenge 2
5. Industry Insights
5.1. Porter's Five Forces Analysis
5.1.1. Bargaining power of supplier
5.1.2. Bargaining power of buyer
5.1.3. Threat of substitute
5.1.4. Threat of new entrant
5.1.5. Degree of competition
5.2. PEST Analysis
5.3. Value Chain Analysis
5.4. Industry Trends
5.5. Graft Versus Host Disease Market by Disease

5.5.1. Graft versus host disease (aGvHD)
5.5.2. Chronic graft versus host disease (cGvHD)

5.6. Graft Versus Host Disease Market by Treatment
5.6.1. mTOR inhibitors,
5.6.2. tyrosine kinase inhibitors,
5.6.3. monoclonal antibodies,
5.6.4. Etanercept,
5.6.5. Thalidomide
5.7. Graft Versus Host Disease Market, by Distribution Channel
5.7.1. Hospital
5.7.2. Retail
5.7.3. On-line
5.8. Graft Versus Host Disease Market, by Region
5.8.1. North America
5.8.2. U.S.
5.8.3. Canada
5.9. Europe
5.9.1. Germany
5.9.2. UK
5.9.3. France
5.9.4. Rest of Europe
5.10. Asia-Pacific
5.10.1. China
5.10.2. Japan
5.10.3. India
5.10.4. Rest of APAC
5.11. LAMEA
5.11.1. Latin America
5.11.2. Middle East
6. Competitive Landscape
6.1. Key Players Analysis
6.2. Strategic Analysis
6.2.1. New Product Developments
6.2.2. Mergers & Acquisitions
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Geographic Expansions
6.2.5. Joint Ventures, Collaborations, Partnerships & Agreements
7. Company Profiles
7.1. Sanofi
7.1.1. Company Overview
7.1.2. Financial Snapshot
7.1.3. Products and Services Offered
7.1.4. Recent Developments
7.2. Novartis AG
7.2.1. Company Overview
7.2.2. Financial Snapshot
7.2.3. Products and Services Offered
7.2.4. Recent Developments
7.3. Neovii Biotech
7.3.1. Company Overview
7.3.1. Financial Snapshot
7.3.2. Products and Services Offered
7.3.3. Recent Developments
7.4. Merck & Co., Inc
7.4.1. Company Overview
7.4.2. Financial Snapshot
7.4.3. Products and Services Offered
7.4.4. Recent Developments
7.5. Astellas Pharma Inc.
7.5.1. Company Overview
7.5.2. Financial Snapshot
7.5.3. Products and Services Offered
7.5.4. Recent Developments
7.6. Soligenix, Inc.
7.6.1. Company Overview
7.6.2. Financial Snapshot
7.6.3. Products and Services Offered
7.6.4. Recent Developments
7.7. Mesoblast Ltd.
7.7.1. Company Overview
7.7.2. Financial Snapshot
7.7.3. Products and Services Offered
7.7.4. Recent Developments
7.8. Johnson & Johnson Services
7.8.1. Company Overview
7.8.2. Financial Snapshot
7.8.3. Products and Services Offered
7.8.4. Recent Developments
7.9. Mallinckrodft
7.9.1. Company Overview
7.9.2. Financial Snapshot
7.9.3. Products and Services Offered
7.9.4. Recent Developments
7.10. Incyte Corporation
7.10.1. Company Overview
7.10.2. Financial Snapshot
7.10.3. Products and Services Offered
7.10.4. Recent Developments

Research Methodology
Global Graft Versus Host Disease Market - Key Segment
Global Graft Versus Host Disease market is segmented into -
By Disease

  • graft versus host disease (aGvHD)
  • chronic graft versus host disease (cGvHD)
    By Treatment

  • mTOR inhibitors

  • tyrosine kinase inhibitors

  • monoclonal antibodies

  • Etanercept

  • Thalidomide.
    By Distribution Channel
  • Hospital
  • Retail
  • Online

    Key Players


    Global Graft Versus Host Disease Market - Competitive Analysis Sanofi
    Novartis AG
    Neovii Biotech
    Merck & Co.
    Inc
    Astellas Pharma Inc.
    Soligenix Mesoblast Ltd.
    Johnson & Johnson Services ElsaLys Biotech SA
    Incyte Corporation
    Kiadis Pharma


  • Research Methodology

    There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, injected humour, or randomised words which don't look even slightly believablThere are many variations of passages.
    Graphic design lorem Ipsum is simply dummy text of the printing and type setting industry. Lorem Ipsum has been the industry's standard dummy text ever since the when an unknown printer took.
    Developement lorem Ipsum is simply dummy text of the printing and type has been the industry's standard dummy text ever since the when an unknown printer took a galley of type and scrambled it to make.
    Graphic design lorem Ipsum is simply dummy text of the printing and type setting industry. Lorem Ipsum has been the industry's standard dummy text ever since the when an unknown printer took.
    ×
    Market Research Report

    Get In Touch

    Contact Info

    Phone number

    (456) 789 10 12

    (456) 789 10 15

    Email address

    demo@gmail.com

    indusinfo@gmail.com

    Address info

    1363-1385 Sunset Blvd Los Angeles